Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin LymphomaBusiness Wire • 02/01/21
Week 5 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 02/01/21
Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week24/7 Wall Street • 01/31/21
Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/30/21
Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the USBusiness Wire • 01/27/21
Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021Business Wire • 01/26/21
Merck Just Scrapped Its Coronavirus Vaccines — Is Merck Stock A Buy?Investors Business Daily • 01/26/21
European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal CancerBusiness Wire • 01/26/21
Merck Scraps 'Inferior' Covid-19 Vaccines; But Shares Recover From DipInvestors Business Daily • 01/25/21
US drug giant Merck drops out the COVID-19 vaccine race, after its 2 vaccine candidates failed to generate a strong immune responseBusiness Insider • 01/25/21